Iohexol
- Generic Name
- Iohexol
- Brand Names
- Omnipaque, Oraltag
- Drug Type
- Small Molecule
- Chemical Formula
- C19H26I3N3O9
- CAS Number
- 66108-95-0
- Unique Ingredient Identifier
- 4419T9MX03
- Background
Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.
- Indication
Iohexol ia used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures.
- Associated Conditions
- -
- Associated Therapies
- -
Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3
- Conditions
- Interventions
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Yale University
- Target Recruit Count
- 80
- Registration Number
- NCT04649229
- Locations
- 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States
Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Ligand Pharmaceuticals
- Registration Number
- NCT04627831
Virtual Colonoscopy Using Omnipaque as a Contrast Agent
- First Posted Date
- 2020-10-09
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT04582500
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
A Study of LY3556050 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2020-08-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 34
- Registration Number
- NCT04156750
- Locations
- 🇺🇸
Covance, Dallas, Texas, United States
Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2
- Conditions
- Interventions
- First Posted Date
- 2019-10-02
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 80
- Registration Number
- NCT04113109
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
- Conditions
- Interventions
- First Posted Date
- 2019-06-25
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 350
- Registration Number
- NCT03997370
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸The Hospital of Central Connecticut, New Britain, Connecticut, United States
A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib on Metformin
- Conditions
- Interventions
- First Posted Date
- 2019-02-01
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT03826602
- Locations
- 🇺🇸
Pharmaceutical Research Associates, Salt Lake City, Utah, United States
Effect of Evolocumab on Coronary Atherosclerosis
- Conditions
- Interventions
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 55
- Registration Number
- NCT03689946
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
Pediatric Risk of Hypothyroidism With Iodinated Contrast Media
- Conditions
- Interventions
- First Posted Date
- 2018-08-15
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- GE Healthcare
- Registration Number
- NCT03631771
A Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy Participants
- First Posted Date
- 2018-06-04
- Last Posted Date
- 2018-06-28
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT03545087
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸Orlando Clinical Research Ctr., Orlando, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.